Neurocrine Biosciences (NBIX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Neurocrine Biosciences

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$156.57+1.43(0.01%)Pre-market

Market Cap

$15.10B

P/E

21.4x

P/S

4.5x

P/B

4.1x

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

How this company scores

ExcellentMetricSide Score: 87/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability22/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 21.4x5y range 19.3x – 771.5x

Currently below its 20-quarter median.

P/S · 4.5x5y range 4.2x – 8.4x

Currently below its 20-quarter median.

P/B · 4.1x5y range 3.8x – 6.7x

Price & Volume

Market Cap $15.10B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.37B
Q. Revenue: $959.00M
TTM EBITDA: $842.10M
TTM Op. Income: $794.80M
Q. Op. Income: $151.50M
TTM Net Income: $705.50M
Q. Net Income: $144.40M
EPS: $1.43
Shares Out.: $101.00M

$3.37B in TTM revenue grew 34.4% YoY, reaching $959.00M last quarter. TTM EBITDA of $842.10M and TTM operating income of $794.80M show growth is flowing through to the bottom line. TTM net income of $705.50M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 18.4%
Op. Margin: 15.8%
Net Margin: 15.1%

Op. margin of 15.8% is down 5.4% YoY — costs are rising relative to revenue. Net margin at 15.1% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 21.4x
P/S Ratio: 4.5x
P/B Ratio: 4.1x

At 21.4x P/E, the stock trades within typical market levels. P/S of 4.5x and P/B of 4.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 40% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $5.36B
Cash: $332.40M
Long-Term Debt: N/A
Book Value: $3.69B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $136.40M
TTM Free Cash Flow: $870.40M
FCF Margin: 25.8%
FCF / Net Income: 1.2

TTM FCF of $870.40M on $136.40M in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.